We conducted a 36-patient, single-arm, open-label, multicenter phase 1/2 study of a PTCV in combination with pembrolizumab (a PD-1 inhibitor) in patients with advanced HCC previously treated with a multityrosine kinase inhibitor (mTKI). Here, PDCD1 is linked to hepatocellular carcinoma.